CTOs on the Move

Celdara Medical

www.celdaramedical.com

 
Celdara Medical gives hope and health to patients by transforming academic innovations into medicines that cure the world`s most challenging diseases. We are a recognized leader with a rich stable of discoveries, developed in concert with premiere research institutions in the US, EU, and beyond. We secure lasting partnerships with inventors and their institutions, and provide the developmental, financial, and business acumen to bridge the gaps between discovery and clinical impact. With robust funding options, operations in greater Boston, Washington DC and New York City, growing affiliates in Seattle and Indianapolis, a wealth of opportunities in our pipeline, and partnerships ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

New Economy Strategies

New Economy Strategies is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quantapore

Quantapore`s novel, high throughput, massively parallel sequencer will allow rapid, affordable and sensitive sequencing of entire genomes. This desktop system will address the need for efficient sequencing. Revenues will be garnered by seeding units into customer facilities, and then by the sale of consumable cartridges; providing rapid growth as the installed base and customer utilization increases.

Moderna

Learn how we’re changing the world of medicine. Discover career opportunities, our product pipeline, and browse media resources. Meet Moderna.

Merck Millipore

Merck Millipore is a Billerica, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cullinan Oncology

Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, Cullinan`s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.